Login to Your Account



Partners, Effector MAPing strategy in CRC combo bid; series C round gets $38.6M

By Randy Osborne
Staff Writer

Monday, July 24, 2017

"Playing chess with the disease" is how CEO Steve Worland describes Effector Therapeutics Inc.'s approach, a translational regulation strategy in cancer that bagged the San Diego-based company $38.6 million in series C money.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription